Express prolongs the life of patients with advanced breast cancer by nearly 16 months, and the long-term clinical results of Novartis CDK4/6 inhibitor are positive

▎WuXi AppTec Content Team Editor Today, Novartis announced that its CDK4/6 inhibitor Kisqali (ribociclib) in combination with fulvestrant as first-line therapy in postmenopausal patients with HR+/HER2- advanced or metastatic breast cancer In the phase 3 clinical trial of fulvestrant, the overall survival of patients was extended by nearly 16 months
.

The press release notes that Kisqali is the first CDK4/6 inhibitor-fulvestrant combination to demonstrate an overall survival benefit in this first-line setting
.

Breast cancer is the most common type of cancer in women worldwide, with approximately 2 million patients diagnosed with breast cancer in 2018
.

Advanced breast cancer patients include metastatic breast cancer patients and locally advanced breast cancer patients
.

Compared with patients with early stage breast cancer, the survival rate of patients with advanced breast cancer is lower, the 5-year survival rate of patients with locally advanced breast cancer is 85%, and the 5-year survival rate of patients with metastatic breast cancer is only 27%
.

Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow cancer progression by inhibiting two cyclin-dependent kinases 4 and 6 (CDK4/6)
.

When these proteins are overactivated, cancer cells can grow and divide too quickly
.

In this latest analysis, at a median follow-up of 5 years, median overall survival was 67.
6 months in the Kisqali combination arm and 51.
8 months in the fulvestrant arm
.

The Kisqali combination therapy reduced the patient's risk of death by 33%
.

Also, the Kisqali combination as first-line therapy delayed the need for patients to receive follow-up chemotherapy by more than a year and a half
.
"The results of this trial continue to demonstrate the survival benefit of
ribociclib in postmenopausal women with advanced breast cancer ," said Dennis J.
Slamon, MD, director of the UCLA Jonsson Comprehensive Cancer Center.
In combination, ribociclib provides oncologists with a CDK4/6 inhibitor that provides consistent benefit in HR+/HER2- breast cancer patients, regardless of their disease characteristics .
" Reference: [1] New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients.
Retrieved May 4, 2022, from https:// -demonstrate-only-kisqali-offers-more-life-first-line-setting-postmenopausal-hrher2-advanced-breast-cancer-patients Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress .
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article .
This article is also not a treatment plan recommendation .
For guidance on treatment options, please visit a regular hospital .